The dual HER2-targeted combination of pertuzumab and trastuzumab, alongside cytotoxic chemotherapy, constitutes the first-line standard of neoadjuvant therapy for patients with HER2-positive breast cancer (Korde et al., 2021). This evidence concerns the gene ERBB2 and breast cancer.